Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
Key near-term readouts (2023) for high-value medicines...
INNOVATION
Key assets* with submission enabling readouts in 2023
KisqaliⓇ
NATALEE trial in adjuvant breast
cancer testing broad patient
population (anatomical stage II
and III), with final analysis
expected in H2 2023
Iptacopan
APPOINT-PNH trial in treatment-
naive patients positive readout;
detailed data presentation in 2023
PNH FDA submission
planned H1 2023
APPLAUSE-IgAN Ph3 readout²
planned in H2 2023
APPEAR-C3G Ph3 readout
planned in H2 2023
PluvictoⓇ
PSMAfore trial in mCRPC
(post-ARDT, pre-taxane) positive
readout; detailed data presentation
planned in 2023
FDA regulatory submission
planned H2 2023
* Unprobabilized peak sales of all asset indications in late-stage development:
> USD 1bn
> USD 2bn
> USD 3bn
1. Based on AJCC prognostic staging. 2. 9 months analysis potentially supporting US Subpart H filing.
11 Investor Relations | Q4 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation